@lastever That's a nice bounce. Off a low base, but nice if you bought the low.

A potential 'cure for cancer' will do that I suppose! (see ASX announcement here)

Hyperbole aside, this does look like big news.

I went back to our recent interview with the Chair, David Williams (also of PolyNovo fame) to see what he said specifically about Inoviq. My AI buddy Claude said this:

1. Inoviq is working on developing more accurate cancer diagnostic tests, especially for breast, pancreatic and prostate cancers. The focus is on finding biomarkers that can predict cancers much earlier than current methods.

2. Inoviq's technology uses exosomes, which is a relatively new area of research looking at cells. The hope is that their exosome-based tests could be disruptive and replace current standard tests like mammograms for breast cancer or PSA tests for prostate cancer. 

3. Inoviq currently has a research product - exosome testing kits that they are selling to researchers around the world. An American distributor is expected to ramp up sales of these kits to researchers fairly quickly.

4. Over the next couple years, Inoviq plans to progress to having a commercial diagnostic test product. Williams believes researcher use of their kits will add to Inoviq's knowledge and patents and help accelerate commercialization. 

5. Key focuses for commercializing a test will be maximizing distribution to doctors and figuring out pricing and reimbursement models. The goal is for it to become a routine test bundled with other standard blood tests.

6. Inoviq's own clinical trial program for their tests is expected to take around two years. 

7. Williams sees potential for Inoviq to merge with other complementary cell therapy companies to enhance their capabilities and chances of success.

In summary, Inoviq is at an earlier stage than Williams' other company Polynovo, but he is optimistic about the potential for their exosome-based technology to provide earlier and more accurate cancer diagnosis compared to current methods. Key near-term milestones are expanding research use of their kits and progressing clinical trials of their diagnostic tests.

I then uploaded today's announcement, and asked Claude.ai if this was hinted at in any way:

Based on the interview with David Williams, there were a few key points that hinted at or suggested the potential for the developments announced in the Inoviq press release:

1. Williams mentioned that Inoviq's exosome technology could potentially be a platform that is applicable not just to diagnostics but also therapeutics. This aligns with the announcement about Inoviq's progress in developing engineered exosomes (EEVs) as a potential cancer therapy.

2. He noted that Inoviq's technology is focused on exosomes derived from cells, which fits with the announcement's mention of immune cell-derived exosomes being used in their therapeutic program.

3. Williams discussed the potential for exosomes to be engineered to target specific cells or deliver therapeutic cargo, which is what Inoviq has demonstrated in their proof-of-concept study with CAR-exosomes targeting breast cancer cells and the potential for drug-loaded exosomes.

4. The announcement highlights Inoviq's EXO-ACE technology for isolating and purifying exosomes at scale. While not mentioned by name, Williams did discuss Inoviq's proprietary technology in the interview.

However, the specific details of the proof-of-concept study, the focus on breast and ovarian cancer, and the in vitro efficacy data were not directly mentioned in the interview. The announcement represents a significant development and progression of Inoviq's exosome therapeutic program that builds upon the platform capabilities and potential that Williams alluded to in the discussion.

And, finally, to help cut through the techno-talk, I asked Claude to explain the announcement to me like i was 12:

Imagine our body is like a big city with lots of different buildings. These buildings are like the cells in our body. Now, these cells send out tiny little packages called exosomes, which are like tiny mail trucks that deliver messages and other important things between the cells.

Inoviq is a company that has figured out a way to make these exosome mail trucks deliver a special message that tells certain cells, specifically cancer cells in the breast, to stop working and disappear. They call these special exosomes "engineered exosomes" or EEVs for short.

In their experiments, they made the exosomes from special cells in our body called immune cells. These immune cells are like the police of our body, always on the lookout for any trouble. Inoviq gave these exosome mail trucks from the immune cells a special "address label" called a CAR that makes sure they only deliver their message to the breast cancer cells.

When they tested these special exosomes in the lab, they found that they were really good at finding and stopping the breast cancer cells. In fact, after just 3 days, 75% of the breast cancer cells that were treated with these exosomes had disappeared.

Inoviq is really excited about this because it means that they might have found a new way to treat breast cancer and possibly other types of cancer too. They are now going to do more experiments to make sure it works well and is safe before they can start testing it in people.

So, in short, Inoviq has developed a clever way to use the body's own little mail trucks (exosomes) to deliver a message that tells cancer cells to stop working, and they're excited to keep working on this new way to treat cancer.

Anyway -- while this is an interesting development, there's a long way to go before any commercial outcomes are seen. Still, something to keep an eye on!

@Parko5 I see what you mean though, it’s just a repeat of what was in that slide deck from April. Goes to show the power of a headline. Must be some people who read ‘kill breast cancer’, clicked buy and went for coffee.

Again, i'm being a bit lazy and leaning on AI here, but I uploaded the April presentation and asked what (if anything) was new in today's ASX announcement:

Here is what it said:

Yes, there are a few key things in the latest announcement from Inoviq that were not mentioned in the April investor presentation:

1. The announcement provides specific details of a proof-of-concept study where engineered exosomes (EEVs) targeting breast cancer were successfully produced and isolated. This study showed that these EEVs, when treated with breast cancer cells, led to 75% of the cancer cells undergoing cell death within 72 hours. These specific results were not included in the presentation.

2. The announcement quantifies the performance of Inoviq's EXO-ACE technology, stating it recovered more than 80% of exosomes from cell-conditioned media with over 95% purity. These specific performance metrics for EXO-ACE were not provided in the presentation.

3. The announcement states that based on the proof-of-concept results, Inoviq will now progress its exosome therapeutics program, initially focusing on immune-cell derived exosome therapeutics for metastatic breast and ovarian cancers. This specific focus on metastatic breast and ovarian cancers for the therapeutics program was not mentioned in the presentation.

4. The potential for engineered exosomes to be loaded with drug cargo such as RNA therapeutics to treat neurological diseases across the blood-brain barrier is mentioned in the announcement but not in the presentation.

So in summary, while the April presentation discussed Inoviq's capabilities and plans in exosome therapeutics in general terms, the latest announcement provides more specific data, technological performance, and program focus that represent advancements beyond what was disclosed in the earlier investor presentation.

@Strawman While this doesnt make me look very intelligent, I loved Claude Ai's explanation of the announcement for a 12 year old. Made it possible for even me to understand. You are really getting me interested in these Ai tools. I have just put a toe in the water and I'm playing with them.

I need this Ai 12 year old filter on 24/7 as I move through the world, to translate everything that's coming at me.

@Strawman

Interesting use of the AI.

And I agree with it. Old news....but just more detail.

So the big question is....why? Why re-announce something?

Here are my thoughts:

• We know a cap raise is coming and they need the SP to move up. So this is probably the start of a few annoucements.
• I'm guessing that somebody looked back at all the previous annoucements and realised that their "cancer killer" work was buried away in a presentation. And this is what leads me to question management! How does this happen? You have the "cancer killer" product and forget to make a seperate annoucement?

Anyway....i would assume as part of the cap raise...there will be a management shakeup. Or at least some new blood.

SP - it is good to see it go up. But unless they keep the newsflow going and a good plan how they will commercialise their exisiting products....it will find it difficult to find a floor price above $1.

I'm still a long term holder.

Agree the announcement is significant as therapy is big.

But they are not in any trial at the moment if I'm not mistaken?

Guess I'm still looking at the past with what happened to EX1

Having Williams on board is good though.

I think I need the 6 year old filter please!

Agree. Theraputics will take 10 plus years till there could be revenue. And will take lots of cash to get to that point.

Hopefully the cap raise says they will use the money as follows:

• Short term:
• Build a decent size team to commercialise their SubB2M and Exo-Net diagnotics that are ready (Should have a few products ready to sell soonish).
• Have cash to fund research for remaining diagnotics (and improvements) and the theraputics division.
• Medium term
• After a couple of years, the diagnostic part of the business takes off. And some of that cash flow can go to growth of dianostics and some of it to the theraputics.

@Parko5 You were on the money about an incoming raise